Access without hype
People affected by substance use deserve clear language about treatment choices, including the limits of evidence, the possibility of benefit, and the risks that cannot be wished away.
Independent information resource
Trevor Millar And The Ibogaine Clinic Question
The central issue is not simply whether ibogaine may help people navigating addiction. It is whether access can be paired with evidence, accountability, and medical safety.
A clear, evidence-first overview for people interested in treatment access, harm reduction, regulatory change, and informed recovery choices.
The question behind the clinic
Trevor Millar became a recognizable figure in Canadian psychedelic advocacy through work that connected community care, harm reduction, and the difficult realities of addiction treatment.
For people considering ibogaine, the relevant question is not a simple endorsement or rejection. It is how a psychoactive treatment with serious cardiac risk can be discussed honestly when patients may be facing severe opioid use disorder, withdrawal symptoms, trauma, or limited access to care.
The debate asks whether an ibogaine clinic can safely function outside hospital-grade systems, and what standards of medical supervision, patient screening, accountability, and aftercare should be non-negotiable.
Ibogaine is an indole alkaloid from the West African shrub Tabernanthe iboga. Its broader cultural history should not be automatically conflated with commercial clinic models; a useful starting point is the reference overview of ibogaine, alongside careful attention to specific treatment settings.
Safety without dismissal
Harm reduction means taking demand seriously while refusing to treat medical screening, emergency planning, or post-treatment support as optional details.
Canadian advocacy
From advocacy to a difficult public conversation
Trevor Millar was a Canadian social entrepreneur who served as chair of the board of directors for MAPS Canada. That role placed Trevor Millar within a wider multidisciplinary association conversation about psychedelic medicine, public policy, and emerging therapeutic models.
Trevor Millar also co-founded Liberty Root Therapy Ltd in British Columbia, where Liberty Root was associated with ibogaine treatments for people experiencing severe substance dependence. The Liberty Root model is important because it made visible the tension between grassroots care and the demands of a medical clinical framework.
In Vancouver and elsewhere in British Columbia, Trevor Millar’s work was often understood through a harm reduction lens. The stated aspiration was holistic and community-based: meet people where they are, take their suffering seriously, and make room for peer support and integration therapy.
That aspiration does not eliminate ethical considerations. Any addiction treatment setting must be candid about what it can document, who is qualified to act, how emergency protocol decisions are made, and how patients are supported after detoxification.
Discussion of Trevor Millar’s later work has continued in a conversation on ibogaine and the future of healing, while a separate discussion of brain trauma and psychedelic therapy illustrates how broad the public discussion has become.
Why opioid withdrawal is central to the interest
Interest in ibogaine has long been tied to opioid use disorder. Acute opioid withdrawal symptoms can be severe, and the prospect of a treatment that may significantly attenuate withdrawal symptoms has shaped demand across formal and informal settings.
Ibogaine acts on multiple neurotransmitter systems simultaneously. It is metabolized in part into noribogaine, an active metabolite described as a serotonin reuptake inhibitor and partial mu-opioid receptor agonist. These mechanisms are part of why researchers examine whether ibogaine and noribogaine influence reward pathways, withdrawal, and substance use.
Descriptions of ibogaine “resetting” dopamine signaling are not a substitute for evidence-based treatment claims. Efficacy, dose, patient selection, psychiatric context, and long-term outcomes all require better research, including clinical trials designed around safety and meaningful follow-up.
For opioid use disorder, established medical options such as methadone and buprenorphine remain part of evidence-based care. The SAMHSA overview of medications for substance use disorders explains why medication, behavioral support, and continuity of care should not be eclipsed by a single intervention.
Demand for a different path does not remove the duty to explain risk, uncertainty, and the work of aftercare.
People sometimes approach ibogaine after repeated difficulty with detoxification, relapse, or conventional addiction treatment. That history deserves respect, but it also increases the importance of medical supervision, mental health assessment, integration therapy, and a realistic post-treatment plan.
Cardiac safety is not a footnote
Ibogaine can block hERG potassium channels and produce concentration-dependent QTc prolongation. QTc prolongation is clinically significant because it can create a risk of torsades de pointes, ventricular tachyarrhythmias, heart arrhythmia, and sudden cardiac arrest.
The risk profile changes with dose, co-occurring conditions, other medications, electrolyte status, and patient history. This is why cardiac safety cannot be inferred from a person’s apparent health or from prior anecdotal treatment experiences.
Safe clinical protocols require patient screening before administration, baseline and continuous 12-lead electrocardiogram monitoring, and blood testing for potassium and magnesium electrolyte levels. A credible emergency protocol, trained practitioners, and clear pathways for escalation are part of medical supervision rather than a marketing extra.
The published literature includes documented concern about cardiotoxicity and mortality; a peer-reviewed review of ibogaine cardiac risk is useful context for understanding why preventable fatal complications are a central concern.
- Screen for cardiac history, medication interactions, substance use patterns, and contraindications.
- Use an electrocardiogram before administration and maintain monitoring suited to the protocol.
- Check potassium and magnesium because electrolyte imbalance can heighten cardiac safety concerns.
- Plan aftercare and post-treatment observation rather than treating detoxification as the end of therapy.
Regulatory realities
Canada, classification, and the grey market
In 2017, Health Canada added ibogaine to the Prescription Drug List. That change closed an unregulated natural health product loophole and made the regulatory landscape more explicit.
The Prescription Drug List status did not create a broadly available, commercially licensed pharmaceutical preparation. Instead, the lack of approved access contributed to a patchwork of international retreat settings, underground clinics, and cross-border treatment choices.
Health Canada’s role is therefore central to the Canadian story: regulation may define a product category, but it does not independently establish clinical efficacy, reliable access, or adequate medical infrastructure.
In the United States, ibogaine remains a controlled substance under federal law. The DEA explanation of federal drug scheduling provides context for why research pathways and clinic access differ across jurisdictions.
The clinic dilemma
Underground care or institutional medicalization?
The central dilemma is whether community-based alternative clinics can safely operate without intensive hospital-grade medical oversight. Underground clinics may emerge where patients feel abandoned by conventional addiction treatment, yet opacity can weaken accountability.
Medicalization can bring standardization, licensed practitioners, formal patient screening, and oversight. It can also create barriers of cost, geography, and gatekeeping that communities organized around harm reduction have historically tried to address.
Neither side of the comparison resolves the question alone. A therapeutic setting should be judged by its safety protocols, transparency, continuity of care, and willingness to put patient welfare ahead of commercial pressure.
A public discussion of candidate screening for ibogaine reflects the practical questions patients ask, but public-facing material is not equivalent to independent medical validation.
Evidence has to catch up with demand
Clinical trials are the clearest route for defining dosing, contraindications, stopping rules, monitoring, and efficacy. They can also clarify whether future psychedelic-assisted treatment should use ibogaine, noribogaine, or other compounds designed to reduce cardiotoxicity.
Research is already expanding beyond opioid use disorder. A Berkeley Center for the Science of Psychedelics discussion of a Navy SEAL’s experience shows why trauma, mental health, and veteran treatment narratives are part of the current conversation, while also underscoring the difference between experience and proof.
The proposed Stanford MISTIC trial discussion points to the need for structured research on magnesium, monitoring, and ibogaine therapy in a defined population.
New interest does not justify premature certainty. Clinical trials must address mortality, cardiac safety, psychiatric complications, long-term substance use outcomes, and the quality of aftercare in a way that can be examined independently.
One longer-form conversation about ibogaine and recovery and a separate podcast episode featuring Trevor Millar add perspective, but neither replaces a clinical framework grounded in reproducible evidence.
What Liberty Root represented
Liberty Root is relevant not because it supplies a universal model, but because it illustrates the values and contradictions within Canadian psychedelic advocacy. Liberty Root joined a conversation about how people with serious addiction could receive care that felt more human, relational, and holistic.
Trevor Millar’s association with Liberty Root also highlights the practical difficulty of translating ceremonial or community care into medical practice. A visionary plant tradition, a psychoactive alkaloid, and a clinic protocol are not interchangeable categories.
For Trevor Millar, harm reduction was not simply a phrase about lower-risk behavior. It was an argument for meeting people amid real withdrawal symptoms, unstable housing, trauma, stigma, and incomplete treatment access. That argument remains significant in Vancouver, British Columbia, and beyond.
At the same time, ethical considerations require practitioners and advocates to distinguish community care from claims of medical safety. Patient screening, an electrocardiogram, electrolyte assessment, medical supervision, and an emergency protocol are not resolved by good intentions.
A music-hosted discussion series on ibogaine themes and a circulating short public video on the topic show how quickly complex treatment questions travel through informal channels.
A quieter way to assess information
Trevor Millar Ibogaine Clinic is a newly launched independent information company helping people understand this question without presenting itself as a treatment provider. Our approach to independence, clarity, and accuracy explains the scope of this resource.
Useful guidance should help readers identify the questions a clinic must answer: How is cardiac safety handled? What does patient screening include? Who has medical responsibility during administration? What happens after detoxification, and how is integration therapy supported?
For a structured view of the information tools we maintain, see the available resource pathways. They are intended to support informed discussion, not to recommend a clinic, a protocol, or a treatment decision.
The recent feature on ibogaine, trauma, and mental health reflects the wider attention around psychedelic medicine. Wider attention makes careful evidence and accountability more important, not less.
Examine the clinic question in detailQuestions, answered carefully
Frequently asked questions
What was Trevor Millar’s role in the Canadian ibogaine movement?
Trevor Millar served as chair of the board of directors for MAPS Canada and co-founded Liberty Root Therapy Ltd in British Columbia. Trevor Millar’s work connected harm reduction with community-based psychedelic care and helped bring the question of ibogaine clinic accountability into wider view.
How does ibogaine assist with severe opioid withdrawal symptoms?
Ibogaine and its metabolite noribogaine have drawn research interest because they may attenuate acute opioid withdrawal symptoms through activity across several neurotransmitter systems. That possibility does not establish efficacy for every patient or replace evidence-based treatment for opioid use disorder, including methadone, buprenorphine, therapy, and ongoing medical care.
What cardiac risks are associated with ibogaine administration?
Ibogaine can cause QTc prolongation, which may increase the risk of heart arrhythmia, torsades de pointes, ventricular tachyarrhythmias, and sudden cardiac arrest. Robust safety protocols include patient screening, a baseline and continuous electrocardiogram, potassium and magnesium testing, medical supervision, and a workable emergency protocol.
How does regulation differ between Canada and other jurisdictions?
Health Canada placed ibogaine on the Prescription Drug List in 2017. Other jurisdictions have different rules, ranging from controlled-substance restrictions to research-only pathways and grey market access. Regulatory status should not be mistaken for a conclusion about treatment safety or therapeutic efficacy.
What is the central issue between underground clinics and medicalization?
Underground clinics can arise in response to unmet need, while institutional medicalization can offer clearer oversight. The unresolved issue is whether any ibogaine clinic can ensure cardiac safety, accountable practitioners, clinical protocols, integration therapy, and aftercare without the safeguards of a formal medical setting.
Where can people find condition-specific context on alcohol use?
For readers comparing substance use contexts, the independent overview at ibogaine for alcohol addiction may help frame questions about evidence, patient screening, safety, and post-treatment support. It should not be treated as individualized medical advice.